← All organizations

Auxillium

For profitContributed to NME

Also known as: Auxilium Pharmaceuticals, Inc. | AUXILIUM PHARMS | AUXILIUM PHARMS INC | AUXILIUM PHARMS LLC

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Sep 1, 2012

Acquired by Endo Pharmaceuticals → Mallinckrodt (2013) on Jan 1, 2014

Timeline

1990s

Feb 28, 1992
theophylline— Marketing Organization
Mar 25, 1994
acrivastine— NDA Secondary Org
Jan 1, 1999
Auxillium— Founded

2010s

Feb 2, 2010
collagenase clostridium histolyticum— NDA Organization
Jan 1, 2013
Actient— Acquired
Jan 1, 2014
Endo Pharmaceuticals— Acquired By

2020s

Mar 1, 2025
Mallinckrodt (2013)— Now

Drugs by trial phase (1 distinct, 6 trials)

Phase 4 (1 own, 0 via acquisition)

collagenase clostridium histolyticum

Indications

Approved for

Studied for

Marketed drugs (9)

Subsidiaries (1 direct, 2 total across the full acquisition tree)

Recent trials (6)

NCT01685437Study directorPhase 3Sep 1, 2012
NCT01430169Study directorPhase 2Sep 1, 2011
NCT01450397CollaboratorPhase 4Mar 1, 2011
NCT01243411Study directorPhase 3Nov 1, 2010
NCT01221623Study directorPhase 3Oct 1, 2010
NCT01221597Study directorPhase 3Sep 1, 2010

Details

Founded: Centerbrook, CT, US Jan 1, 1999
First NDA: Feb 2, 2010
Last known activity: Sep 1, 2012

Notes

Acquired by Endo in 2015